AU2012316912B9 - Novel heterocyclic derivatives and their uses - Google Patents

Novel heterocyclic derivatives and their uses Download PDF

Info

Publication number
AU2012316912B9
AU2012316912B9 AU2012316912A AU2012316912A AU2012316912B9 AU 2012316912 B9 AU2012316912 B9 AU 2012316912B9 AU 2012316912 A AU2012316912 A AU 2012316912A AU 2012316912 A AU2012316912 A AU 2012316912A AU 2012316912 B9 AU2012316912 B9 AU 2012316912B9
Authority
AU
Australia
Prior art keywords
compound
formula
triazolo
pyrazin
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012316912A
Other languages
English (en)
Other versions
AU2012316912B2 (en
AU2012316912A1 (en
AU2012316912A8 (en
Inventor
Sung Oh Ahn
Sun Young Han
Pil Su Ho
Hye Jung Kim
Jung Sook Kim
Won Il Lee
Woul Seong PARK
Dong Oh Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C&C Research Laboratories
Original Assignee
C&C Research Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Research Laboratories filed Critical C&C Research Laboratories
Publication of AU2012316912A1 publication Critical patent/AU2012316912A1/en
Publication of AU2012316912A8 publication Critical patent/AU2012316912A8/en
Publication of AU2012316912B2 publication Critical patent/AU2012316912B2/en
Application granted granted Critical
Publication of AU2012316912B9 publication Critical patent/AU2012316912B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2012316912A 2011-09-30 2012-09-28 Novel heterocyclic derivatives and their uses Active AU2012316912B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2011-0100369 2011-09-30
KR20110100369 2011-09-30
KR10-2012-0033444 2012-03-30
KR20120033444 2012-03-30
PCT/KR2012/007965 WO2013048214A2 (en) 2011-09-30 2012-09-28 Novel heterocyclic derivatives and their uses

Publications (4)

Publication Number Publication Date
AU2012316912A1 AU2012316912A1 (en) 2014-03-20
AU2012316912A8 AU2012316912A8 (en) 2014-04-10
AU2012316912B2 AU2012316912B2 (en) 2017-04-20
AU2012316912B9 true AU2012316912B9 (en) 2017-04-27

Family

ID=47996667

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012316912A Active AU2012316912B9 (en) 2011-09-30 2012-09-28 Novel heterocyclic derivatives and their uses

Country Status (26)

Country Link
US (1) US9586959B2 (cg-RX-API-DMAC10.html)
EP (2) EP3461825B1 (cg-RX-API-DMAC10.html)
JP (1) JP6031107B2 (cg-RX-API-DMAC10.html)
KR (1) KR101800749B1 (cg-RX-API-DMAC10.html)
CN (1) CN103889986B (cg-RX-API-DMAC10.html)
AR (1) AR088085A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012316912B9 (cg-RX-API-DMAC10.html)
BR (1) BR112014007645A2 (cg-RX-API-DMAC10.html)
CA (1) CA2848154C (cg-RX-API-DMAC10.html)
CY (1) CY1121292T1 (cg-RX-API-DMAC10.html)
DK (2) DK2760865T3 (cg-RX-API-DMAC10.html)
ES (2) ES2687693T3 (cg-RX-API-DMAC10.html)
FI (1) FI3461825T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20181310T1 (cg-RX-API-DMAC10.html)
HU (2) HUE062842T2 (cg-RX-API-DMAC10.html)
LT (2) LT2760865T (cg-RX-API-DMAC10.html)
MX (1) MX355795B (cg-RX-API-DMAC10.html)
PL (2) PL3461825T3 (cg-RX-API-DMAC10.html)
PT (2) PT3461825T (cg-RX-API-DMAC10.html)
RS (2) RS64575B1 (cg-RX-API-DMAC10.html)
RU (1) RU2628074C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201400484RA (cg-RX-API-DMAC10.html)
SI (2) SI3461825T1 (cg-RX-API-DMAC10.html)
TR (1) TR201814710T4 (cg-RX-API-DMAC10.html)
TW (1) TWI551600B (cg-RX-API-DMAC10.html)
WO (1) WO2013048214A2 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015000715A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN112010772A (zh) * 2016-01-26 2020-12-01 赵鸣 5-氨基酮戊酸及其衍生物的盐化合物和应用
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018111003A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2018139876A1 (ko) * 2017-01-26 2018-08-02 동화약품주식회사 신규한 [1, 2, 4] 트리아졸로 [4, 3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 bet 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
JP6876833B2 (ja) * 2017-02-27 2021-05-26 ▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司Ｂｅｔｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｆｇｆｒ阻害剤およびその使用
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー／エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
TW202317568A (zh) * 2021-06-22 2023-05-01 丹麥商理奧藥品公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺半琥珀酸鹽之新穎結晶形式
TW202428578A (zh) * 2022-09-29 2024-07-16 韓商Ｊｗ製藥公司 １－（８－溴化吡啶并［２，３－ｅ］［１，２，４］三唑并［４，３－ａ］吡嗪－４－基）－ｎ－甲基吖丁啶－３－胺之新穎結晶型
AU2023348200A1 (en) * 2022-09-29 2025-03-27 Jw Pharmaceutical Corporation A process for the manufacture of salts and crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine and novel crystalline forms
TW202425977A (zh) * 2022-09-30 2024-07-01 韓商Ｊｗ製藥公司 １－（８－溴化吡啶并［２，３－ｅ］［１，２，４］三唑并［４，３－ａ］吡嗪－４－基）－ｎ－甲基吖丁啶－３－胺單琥珀酸鹽之新穎結晶型
CN116554092B (zh) * 2023-05-18 2026-07-17 上海锐谱医药科技有限公司 一种制备新药砌块(6-甲酰基吡啶-3-基)氨基甲酸叔丁酯的方法
US12173001B1 (en) 2024-01-16 2024-12-24 King Faisal University Pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidines as CK2 inhibitors
US12122775B1 (en) 2024-01-16 2024-10-22 King Faisal University Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors
US12129252B1 (en) 2024-02-15 2024-10-29 King Faisal University Pyrrolo[2,3-c][2,6]naphthyridine-8-carboxylic acids as CK2 inhibitors
CN119732334A (zh) * 2024-11-20 2025-04-01 华中科技大学同济医学院附属同济医院 一种儿童炎症性肠病大鼠模型的构建方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
US5070086A (en) * 1987-12-23 1991-12-03 Schering Corporation Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds
CA2310072A1 (en) * 1997-11-11 1999-05-20 Hiroyuki Ohno Fused pyrazine compounds
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
JP2000319277A (ja) * 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
EP1613629A1 (en) * 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US20090143392A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
SI2268618T1 (sl) * 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
JP2012502067A (ja) 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
CN100580335C (zh) * 2008-09-11 2010-01-13 艾欧史密斯(中国)热水器有限公司 承压式太阳能热水器
ES2550101T3 (es) * 2008-12-17 2015-11-04 Merck Patent Gmbh Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
EP2389379A1 (en) 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011060207A1 (en) * 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
D1 : JONATHAN T. REEVES AND AL: "Copper catalyzed annullation of 2-formylazoles with o-aminoiodoarenes", JOURNAL OF ORGANIC CHEMISTRY, vol. 75, 1 January 2010, pages 992-994 *
D10 : DESMOND J. BROWN AND AL: "Triazolopteridines. Simple s-triazolo[3,4-h]pteridines and some [5,1-h] and [4,3-a] isomers", AUTRALIAN JOURNAL OF CHEMISTRY, vol. 34, 1 January 1981, pages 2635-2639 *
D11 : JOSEPH WEINSCTOCK AND AL: "pteridines. VII. Some 2,4-diamino-6-phenylpteridines", JOURNAM OF MEDICINAL CHEMISTRY, vo l . 11, no. 3, 1 January 1968, pages 557-560 *
D12 : US 2009/0075980 A1 *
D13 : Bowie, R.: Journal of the Chemical Society (Section) D: Chemical Communications, 9, 1970, 565 *
D2 : STEPHEN A. HITCHCOCK AND AL: "Structure-brain exposure relationships", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 26, 28 December 2006, pages 7559-7583 *
D3 : STEFANIA BUTINI AND AL: "Novel, potent, and selective qinoxaline-based 5-HT3 receptor ligands. Further structure-activity relationships . . .", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, 1 January 2009, pages 6946-6950 *
D4 : CAMPIANI GIUSEPPE ET AL: "Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT3 receptor agonists . . .", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEICAL SOCIETY, US, vol. 42, no. 21, 1 January 1999, pages 4362-4379 *
D5 : BLANCHE ET AL: "heterocyclizations in the pyridoA2,3-bUpyrazine series", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 31, no. 1, 1 January 1994, pages 161-166 *
D6 : WO 1999/045009 A1 *
D7 : US 2009/0143392 A1 *
D8 : PRUNIER H ET AL: "Novel and Selective Partial Agonists of 5-HT3 Receptors . . .", JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vo l . 40, no. 12, 1 January 1997 (1997-01-01), pages 1808-1819 *
D9 : UNCITI-BROCETA A ET AL: "Synthesis of 9-alkyl-6-amino[l,2,4]triazolo[3,4-c]-5-az aquinoxalines. Mild and effective SNAr amination of . . .", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 51, no. 17, 28 April 2010, pages 2262-2264 *

Also Published As

Publication number Publication date
JP6031107B2 (ja) 2016-11-24
EP2760865A2 (en) 2014-08-06
DK2760865T3 (en) 2018-10-08
KR20140090984A (ko) 2014-07-18
RS57854B1 (sr) 2018-12-31
PL3461825T3 (pl) 2023-10-30
AU2012316912B2 (en) 2017-04-20
US9586959B2 (en) 2017-03-07
WO2013048214A3 (en) 2013-05-23
ES2954303T3 (es) 2023-11-21
ES2687693T3 (es) 2018-10-26
KR101800749B1 (ko) 2017-11-24
PT2760865T (pt) 2018-11-05
MX355795B (es) 2018-04-30
EP3461825A1 (en) 2019-04-03
WO2013048214A2 (en) 2013-04-04
SI2760865T1 (sl) 2018-10-30
HUE040374T2 (hu) 2019-03-28
JP2014531458A (ja) 2014-11-27
HRP20181310T1 (hr) 2018-10-19
LT2760865T (lt) 2018-09-25
PL2760865T3 (pl) 2018-12-31
US20140315888A1 (en) 2014-10-23
MX2014003042A (es) 2014-05-28
HRP20230893T1 (hr) 2023-11-24
TWI551600B (zh) 2016-10-01
EP2760865A4 (en) 2015-03-18
FI3461825T3 (fi) 2023-08-17
AU2012316912A1 (en) 2014-03-20
EP3461825B1 (en) 2023-06-07
AU2012316912A8 (en) 2014-04-10
RU2014115478A (ru) 2015-11-10
RS64575B1 (sr) 2023-10-31
PT3461825T (pt) 2023-09-11
CN103889986B (zh) 2017-07-21
CA2848154A1 (en) 2013-04-04
CN103889986A (zh) 2014-06-25
EP2760865B1 (en) 2018-07-11
LT3461825T (lt) 2023-08-25
SI3461825T1 (sl) 2023-11-30
CA2848154C (en) 2020-04-28
BR112014007645A2 (pt) 2017-04-18
HUE062842T2 (hu) 2023-12-28
AR088085A1 (es) 2014-05-07
CY1121292T1 (el) 2020-05-29
TR201814710T4 (tr) 2019-01-21
TW201321381A (zh) 2013-06-01
RU2628074C2 (ru) 2017-08-14
SG11201400484RA (en) 2014-10-30
DK3461825T3 (da) 2023-08-14

Similar Documents

Publication Publication Date Title
AU2012316912B2 (en) Novel heterocyclic derivatives and their uses
AU2019216728B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
AU2018388406B2 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
EP3807270B1 (en) Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
KR101785257B1 (ko) 신규한 트리사이클릭 화합물
KR20110046514A (ko) 피리미딘 화합물, 조성물 및 사용 방법
WO2009097490A1 (en) 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
EP2858995A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
EP3877388B1 (en) 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
JP2024512740A (ja) 例えばがんの処置のためのＳＨＰ２阻害剤としての（Ｓ）－１－（５－（（ピリジン－３－イル）チオ）ピラジン－２－イル）－４’Ｈ，６’Ｈ－スピロ［ピペリジン－４，５’－ピロロ［１，２－ｂ］ピラゾール］－４’－アミン誘導体及び同様の化合物
TW202334093A (zh) 雜環醯胺及其使用方法
WO2010043633A1 (en) 2h-pyrazolo [4,3-d]pyrimidin-5-amine derivatives as h4 histamine receptor antagonists for the treatment of allergic, immunological and inflammatory diseases
HK1196820B (en) Novel heterocyclic derivatives and their uses
HK40006979A (en) Novel heterocyclic derivatives and their uses
HK1196820A (en) Novel heterocyclic derivatives and their uses
WO2025111547A1 (en) 2,3-dihydropyrollopyridine carboxamide compounds and methods of use thereof
EA042323B1 (ru) Гетеробициклические соединения для ингибирования активности shp2
NZ624021B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 11 , PAGE(S) 1492 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME C&C RESEARCH LABORATORIES, APPLICATION NO. 2012316912, UNDER INID (72) CORRECT THE CO-INVENTOR TO LEE, WON IL

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)